Related Experiment Video
Updated: Jun 20, 2025
Microvascular Decompression: Salient Surgical Principles and Technical Nuances
Published on: July 5, 2011
[Benefits and Pitfalls of Re-Operation for Recurrent Meningioma]
1Department of Neurosurgery, Tokyo Women's Medical University.
Abstract:
Malignant forms of meningioma, such as atypical and anaplastic meningiomas, commonly relapse. Recently, there have been many reports elucidating the molecular biological mechanisms underlying meningioma recurrence. Tumors with loss of CDKN(cyclin dependent kinase)2A and 2B or lack of the tri-methylation of lysine 27 on histone H3 protein have a particularly high recurrence rate. In general, primary treatment for recurrent meningiomas comprises stereotactic radiosurgery(SRS)or stereotactic radiotherapy(SRT). However, re-operation is recommended for SRS-, SRT-refractory tumors. One of the benefits of reoperation is that it allows tumor control while decompressing the normal tissue, and changing the tumor microenvironment. Another is that it facilitates the acquisition of pathological and molecular genetic information, which can enable clinicians to recommend precision medicine. However, during reoperation, it is often difficult to detach the tumor from the surrounding brain tissue and cranial nerves because of severe adhesion. In cases of malignant meningiomas with multiple relapses, it is important to share the purpose and goal of the surgery with the patients and their families. In other words, which is being prioritized more, a high resection rate or functional outcomes? Furthermore, salvage surgery should also be a consideration.
Insights
Malignant meningiomas often recur, especially those with specific genetic alterations. Reoperation offers benefits for refractory tumors but requires careful consideration of surgical goals and patient outcomes.
Area of Science:
- Neuro-oncology
- Molecular Biology
- Surgical Oncology
Background:
- Malignant meningiomas (atypical, anaplastic) have high recurrence rates.
- Specific molecular markers like CDKN2A/2B loss and H3K27 trimethylation loss correlate with recurrence.
- Recurrent meningiomas are typically treated with stereotactic radiosurgery (SRS) or radiotherapy (SRT).
Purpose of the Study:
- To discuss the role and challenges of reoperation for recurrent meningiomas, particularly those refractory to SRS/SRT.
- To highlight the benefits of reoperation, including tumor control, decompression, and molecular profiling for precision medicine.
- To emphasize the importance of patient-centered decision-making regarding resection rates versus functional outcomes in salvage surgery.
Main Methods:
- Review of current literature on meningioma recurrence and treatment strategies.
- Discussion of surgical considerations for reoperation, including adhesions and functional preservation.
- Emphasis on molecular diagnostics and precision medicine in managing recurrent malignant meningiomas.
Main Results:
- Reoperation is recommended for SRS/SRT-refractory recurrent meningiomas.
- Benefits include tumor control, normal tissue decompression, and obtaining molecular data for targeted therapy.
- Challenges include severe adhesions to surrounding brain and cranial nerves, necessitating careful surgical planning.
Conclusions:
- Reoperation is a crucial salvage option for recurrent malignant meningiomas.
- Balancing maximal resection with functional outcomes is essential and requires shared decision-making with patients.
- Molecular insights from re-biopsy can guide subsequent precision treatment strategies.
